Cytokinetics And JI XING Announce Expansion Of Collaboration To Include Licensing Of Omecamtiv Mecarbil In China; Cytokinetics To Receive $70M In Committed Capital Plus Up To An Additional $330M In Potential Milestone Payments Plus Royalties